Skip to main content
. 2010 Nov 17;36(1):19–28. doi: 10.1159/000321712

Table 7.

Details of excluded studies of conditions not represented in the review

Source/ condition Design Population/ denominator Timescale Case ascertainment method Diagnostic method Outcome
Schrag et al. (1999) [12] MSA/PSP Population-based study of incidence and prevalence 15 general practices from a linkage scheme in the London region; population of 121,608 Prevalence on July 1, 1997 Computerised records screened, with deliberate overascertainment to include all possible cases; neurologist reviewed eligible records and excluded where appropriate; 241 eligible patients, 202 agreed to be assessed for diagnosis Computerised records reviewed; neurological interview and assessment including questionnaires and video to capture neurological symptoms; longitudinal assessments to identify developing symptoms of conditions
  • –

    PSP: 5 diagnosed with probable PSP and 1 possible PSP; crude prevalence of 4.9/100,000 (95% CI: 1.8–10.7); probable only cases – prevalence of 4.1/100,000

  • –

    MSA: 2 diagnosed with probable MSA, 1 possible MSA; crude prevalence of 3.3/100,000 (95% CI: 0.9–8.4); probable only cases – prevalence of 1.6/100,000
Craig et al. (2004) [11] SCA6 Population-based study of prevalence North-east government region; population of 2,516,500 Prevalence on June 30, 2001 SCA6 families identified and studied Molecular genetic and haplotype analyses 32 affected individuals from 16 genealogically distinct families; DNA only available for 26; minimum prevalence of 1.59/100,000 (95% CI: 1.04–2.14) in population aged over 16 years, and of 3.18/100,000 (95% CI: 2.08–4.28) in those >45 years old
Craig et al. (2005) [10] SCA17 Population-based study of prevalence North-east government region; population of 2,516,500 Prevalence on June 30, 2001 192 families with undiagnosed ataxia and 90 families with suspected Huntington's disease studied Molecular genetic and haplotype analyses 2 patients identified with CAG expansion greater than control; each had an affected sister; minimum prevalence of 0.16/100,000 (95% CI, upper value: 0.31)

MSA = Multiple system atrophy; PSP = progressive supranuclear palsy; SCA = spinocerebellar ataxia.